• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Jean-Marc Huet, Bristol-Myers Squibb

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2009
Volume 0
Issue 0

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.

Jean-Marc Huet

CFO and Executive Vice President, Bristol-Myers Squibb

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face. That's why BMS is executing a clear strategy to become a leading biopharma company while remaining focused on operational excellence and strengthening our balance sheet. What is needed now more than ever is the ability to turn challenges into opportunities; we're working to make sure BMS is well positioned to do so.

An innovative environment naturally creates leadership, and provides opportunities for successful, driven people. I make sure that the people whom I work with have what they need in order to be successful. We're all doers here, and that spirit will help us transform into the biopharma company we know we can be.

Related Videos